King Wealth Management Group’s Protagonist Therapeutics PTGX Stock Holding History

King Wealth Management Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$490K	Hold	4,000	–	–	0.05%	113
2026 Q1	$422K	Hold	4,000	–	–	0.05%	115
2025 Q4	$349K	Sell	4,000 -2,000	-33%	-$164K	0.04%	126
2025 Q3	$399K	Hold	6,000	–	–	0.05%	114
2025 Q2	$332K	Hold	6,000	–	–	0.05%	123
2025 Q1	$290K	Hold	6,000	–	–	0.04%	126
2024 Q4	$232K	Hold	6,000	–	–	0.03%	137
2024 Q3	$270K	Sell	6,000 -6,000	-50%	-$242K	0.04%	119
2024 Q2	$416K	Hold	12,000	–	–	0.07%	95
2024 Q1	$347K	Hold	12,000	–	–	0.06%	104
2023 Q4	$275K	Hold	12,000	–	–	0.05%	112
2023 Q3	$200K	Hold	12,000	–	–	0.04%	136
2023 Q2	$331K	Hold	12,000	–	–	0.07%	106
2023 Q1	$276K	Sell	12,000 -10,000	-45%	-$168K	0.06%	121
2022 Q4	$240K	Hold	22,000	–	–	0.06%	121
2022 Q3	$185K	Hold	22,000	–	–	0.05%	141
2022 Q2	$174K	Hold	22,000	–	–	0.04%	150
2022 Q1	$521K	Hold	22,000	–	–	0.1%	88
2021 Q4	$752K	Hold	22,000	–	–	0.14%	76
2021 Q3	$390K	Hold	22,000	–	–	0.08%	112
2021 Q2	$987K	Hold	22,000	–	–	0.2%	69
2021 Q1	$570K	Hold	22,000	–	–	0.13%	84
2020 Q4	$444K	Hold	22,000	–	–	0.1%	97
2020 Q3	$430K	Hold	22,000	–	–	0.11%	95
2020 Q2	$389K	Hold	22,000	–	–	0.11%	93
2020 Q1	$155K	Hold	22,000	–	–	0.07%	130
2019 Q4	$155K	Buy	22,000 +5,000	+29%	+$49.7K	0.04%	139
2019 Q3	$204K	Hold	17,000	–	–	0.06%	135
2019 Q2	$206K	Sell	17,000 -2,500	-13%	-$27.6K	0.06%	130
2019 Q1	$245K	Sell	19,500 -9,500	-33%	-$83.9K	0.08%	116
2018 Q4	$195K	Buy	+29,000	New	+$230K	0.07%	119

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

King Wealth Management Group's PTGX Position: Q2 2026 in Review

King Wealth Management Group held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 4,000 shares worth $490K. The position accounts for 0.05% of the portfolio, ranked #113.

King Wealth Management Group first reported a position in PTGX in Q4 2018 and has held it in 31 quarters since. The position peaked at $987K in Q2 2021. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

King Wealth Management Group held 4,000 shares of Protagonist Therapeutics worth $490K as of Q2 2026.
King Wealth Management Group left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up 0.05% of King Wealth Management Group's portfolio in Q2 2026, its #113 holding.
King Wealth Management Group first reported a position in Protagonist Therapeutics in Q4 2018 and has held it in 31 quarters since.
King Wealth Management Group's Protagonist Therapeutics position peaked at $987K in Q2 2021.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on King Wealth Management Group's 13F filing for Q2 2026, filed 5 Aug 2026.